Vanguard Personalized Indexing Management LLC Buys 19,826 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Edwards Lifesciences by 31.4%, acquiring an additional 19,826 shares during the second quarter, bringing their total holdings to 82,969 shares worth approximately $6.49 million.
• Several other institutional investors have also significantly increased their positions in Edwards Lifesciences, including Nuveen LLC and Woodline Partners LP, reflecting growing interest in the medical research company.
• Edwards Lifesciences reported $0.67 earnings per share (EPS) for the last quarter, exceeding analysts' expectations, and forecasts an EPS of 2.400-2.500 for FY 2025.

Vanguard Personalized Indexing Management LLC boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 31.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 82,969 shares of the medical research company's stock after purchasing an additional 19,826 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Edwards Lifesciences were worth $6,489,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Nuveen LLC bought a new position in Edwards Lifesciences during the first quarter valued at approximately $330,881,000. Jennison Associates LLC lifted its position in Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after purchasing an additional 2,576,383 shares during the period. Mirova US LLC lifted its position in Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company's stock valued at $229,257,000 after purchasing an additional 1,054,301 shares during the period. Woodline Partners LP increased its holdings in Edwards Lifesciences by 7,805.0% during the first quarter. Woodline Partners LP now owns 825,358 shares of the medical research company's stock valued at $59,822,000 after buying an additional 814,917 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in Edwards Lifesciences by 339.7% during the first quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company's stock valued at $65,381,000 after buying an additional 709,648 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $72.94 on Tuesday. The firm has a fifty day moving average price of $77.95 and a 200-day moving average price of $76.18. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a market cap of $42.82 billion, a PE ratio of 10.49, a price-to-earnings-growth ratio of 3.55 and a beta of 1.05. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the prior year, the company posted $0.70 earnings per share. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Evercore ISI set a $88.00 target price on shares of Edwards Lifesciences and gave the company an "outperform" rating in a report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.